| Index | - | P/E | 9.55 | EPS (ttm) | 4.09 | Insider Own | - | Shs Outstand | 4.41B | Perf Week | 0.57% |
| Market Cap | 172.33B | Forward P/E | 11.70 | EPS next Y | 3.34 | Insider Trans | - | Shs Float | 3.17B | Perf Month | 1.11% |
| Enterprise Value | 186.86B | PEG | 1.44 | EPS next Q | - | Inst Own | 7.33% | Short Float | 1.00% | Perf Quarter | -21.38% |
| Income | 18.19B | P/S | 3.35 | EPS this Y | -4.70% | Inst Trans | 0.00% | Short Ratio | 2.56 | Perf Half Y | -5.15% |
| Sales | 51.45B | P/B | 5.10 | EPS next Y | -0.69% | ROA | 19.57% | Short Interest | 31.62M | Perf YTD | -23.25% |
| Book/sh | 7.65 | P/C | 25.10 | EPS next 5Y | 6.63% | ROE | 59.09% | 52W High | 64.16 -39.14% | Perf Year | -26.85% |
| Cash/sh | 1.56 | P/FCF | 23.47 | EPS past 3/5Y | 26.31% 20.36% | ROIC | 29.73% | 52W Low | 35.12 11.19% | Perf 3Y | -61.17% |
| Dividend Est. | 1.16 (2.97%) | EV/EBITDA | 6.61 | Sales past 3/5Y | 23.15% 19.19% | Gross Margin | 80.65% | Volatility | 1.32% 1.64% | Perf 5Y | -23.69% |
| Dividend TTM | 1.80 (4.60%) | EV/Sales | 3.63 | EPS Y/Y TTM | 24.62% | Oper. Margin | 43.13% | ATR (14) | 0.85 | Perf 10Y | 96.82% |
| Dividend Ex-Date | Aug 17, 2026 | Quick Ratio | 0.66 | Sales Y/Y TTM | 22.16% | Profit Margin | 35.35% | RSI (14) | 45.64 | Recom | 2.46 |
| Dividend Gr. 3/5Y | 29.23% 21.58% | Current Ratio | 0.87 | EPS Q/Q | -1.03% | SMA20 | 1.70% | Beta | 0.72 | Target Price | 40.00 |
| Payout | 44.64% | Debt/Eq | 0.67 | Sales Q/Q | 4.58% | SMA50 | -6.82% | Rel Volume | 0.69 | Prev Close | 39.43 |
| Employees | 68,794 | LT Debt/Eq | 0.61 | Earnings | Nov 04 | SMA200 | -12.61% | Avg Volume | 12.95M | Price | 39.05 |
| IPO Date | Apr 30, 1981 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 22.69% 9.58% | Net Debt/EBITDA | 0.54 | Volume | 8,986,131 | Change | -0.96% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-12-26 | Reiterated | BMO Capital | Market Perform | $47 → $40 |
| Sep-11-26 | Downgrade | Morgan Stanley | Equal Weight → Underweight | $42 → $40 |
| Aug-12-26 | Reiterated | Berenberg Bank | $47 | |
| Aug-06-26 | Reiterated | BMO Capital | Market Perform | $45 → $47 |
| Mar-02-26 | Downgrade | Goldman Sachs | Buy → Neutral | |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Feb-05-26 | Reiterated | BMO Capital | Market Perform | $57 → $45 |
| Jan-26-26 | Reiterated | BMO Capital | Market Perform | $46 → $57 |
| Dec-10-25 | Reiterated | HSBC | Hold | $47 → $54 |
| Dec-08-25 | Downgrade | Argus Research | Buy → Hold |
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 51,449 | 46,707 | 42,116 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 9,954 | 8,884 | 6,457 | — | — | — | — | — | — | |
| Gross Profit | 41,496 | 37,823 | 35,659 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10,124 | 10,621 | 9,771 | — | — | — | — | — | — | |
| Research and Development | 9,071 | 7,864 | 6,970 | — | — | — | — | — | — | |
| Other Operating Expense | 97 | 46 | 306 | — | — | — | — | — | — | |
| Operating Income | 22,203 | 19,292 | 18,612 | — | — | — | — | — | — | |
| Interest Expense | 781 | 636 | 238 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1,821 | 1,071 | 71 | — | — | — | — | — | — | |
| Net Income Before Taxes | 23,243 | 19,728 | 18,446 | — | — | — | — | — | — | |
| Income Taxes | 5,048 | 4,248 | 3,800 | — | — | — | — | — | — | |
| Consolidated Net Income | 18,194 | 15,480 | 14,646 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 18,194 | 15,480 | 14,646 | — | — | — | — | — | — | |
| Net Income | 18,194 | 15,480 | 14,646 | — | — | — | — | — | — | |
| EPS (Recurring) | 4.10 | 3.48 | 3.29 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.10 | 3.48 | 3.29 | — | — | — | — | — | — | |
| EPS (Diluted) | 4.09 | 3.48 | 3.28 | — | — | — | — | — | — | |
| EBITDA | 28,262 | 23,686 | 21,455 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 9.55 | 14.62 | 26.21 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.36 | 4.85 | 9.10 | — | — | — | — | — | — | |
| Gross Margin | 80.65 | 80.98 | 84.67 | — | — | — | — | — | — | |
| Operating Margin | 43.16 | 41.30 | 44.19 | — | — | — | — | — | — | |
| Net Margin | 35.36 | 33.14 | 34.78 | — | — | — | — | — | — | |
| Shares Outstanding | 4,428 | 4,448 | 4,454 | — | — | — | — | — | — | |
| Market Capitalization | 172,913 | 226,314 | 383,133 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |